(GNFT) Genfit S.A. - Overview
Stock: Elafibranor, NIS4, GNS561, VS-01, NTZ
| Risk 5d forecast | |
|---|---|
| Volatility | 61.2% |
| Relative Tail Risk | -9.53% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.19 |
| Alpha | 57.71 |
| Character TTM | |
|---|---|
| Beta | 0.081 |
| Beta Downside | 0.463 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.09% |
| CAGR/Max DD | 0.31 |
Description: GNFT Genfit S.A. January 02, 2026
Genfit S.A. (NASDAQ: GNFT) is a late-stage French biopharma focused on metabolic and liver disorders, operating a diversified pipeline that includes the Phase III candidate Elafibranor for primary biliary cholangitis, the NIS4 blood-based diagnostic for non-alcoholic steatohepatitis (NASH), and several early-stage assets such as VS-01 (UCD/OAD), GNS561 (cholangiocarcinoma), and VS-01-ACLF/Nitazoxanide (acute-on-chronic liver failure). The company leverages strategic licensing deals-most notably with Labcorp for NASHnext and with Genoscience Pharma for GNS561-to accelerate commercialization pathways.
Key quantitative signals (as of the latest 2023 filing) show a cash runway of roughly €120 million, a 2023 R&D spend of €85 million (≈ 30 % of total expenses), and a net-loss of €150 million, reflecting heavy investment in late-stage trials. The NASH market is projected to exceed $30 billion by 2030, driven by rising obesity and diabetes prevalence, while the FDA’s recent guidance on surrogate endpoints could shorten approval timelines for blood-based diagnostics like NIS4. Additionally, Genfit’s partnership with Labcorp provides access to a U.S. diagnostic distribution network covering over 200 clinical labs, potentially accelerating market penetration.
If you want a deeper, data-driven view of GNFT’s valuation and risk profile, the ValueRay platform offers granular financial models and scenario analysis that can help you assess the upside versus the cash-burn risk.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -16.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA 9.28 > 1.0 |
| NWC/Revenue: 94.49% < 20% (prev 365.9%; Δ -271.5% < -1%) |
| CFO/TA -0.21 > 3% & CFO -45.3m > Net Income -16.5m |
| Net Debt (31.4m) to EBITDA (1.39m): 22.54 < 3 |
| Current Ratio: 3.74 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.8m) vs 12m ago 0.17% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 61.70% > 50% (prev 11.73%; Δ 49.97% > 0%) |
| Interest Coverage Ratio: -0.26 > 6 (EBITDA TTM 1.39m / Interest Expense TTM 7.12m) |
Altman Z'' -5.10
| A: 0.53 (Total Current Assets 155.4m - Total Current Liabilities 41.6m) / Total Assets 216.7m |
| B: -1.84 (Retained Earnings -399.4m / Total Assets 216.7m) |
| C: -0.01 (EBIT TTM -1.85m / Avg Total Assets 195.3m) |
| D: -2.35 (Book Value of Equity -386.7m / Total Liabilities 164.2m) |
| Altman-Z'' Score: -5.10 = D |
Beneish M -0.16
| DSRI: 0.19 (Receivables 36.9m/32.7m, Revenue 120.5m/20.4m) |
| GMI: 0.99 (GM 99.75% / 98.33%) |
| AQI: 0.81 (AQ_t 0.25 / AQ_t-1 0.30) |
| SGI: 5.91 (Revenue 120.5m / 20.4m) |
| TATA: 0.13 (NI -16.5m - CFO -45.3m) / TA 216.7m) |
| Beneish M-Score: -0.16 (Cap -4..+1) = D |
What is the price of GNFT shares?
Over the past week, the price has changed by +4.73%, over one month by +16.10%, over three months by +68.09% and over the past year by +62.10%.
Is GNFT a buy, sell or hold?
What are the forecasts/targets for the GNFT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.5 | 39.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 6.7 | 9% |
GNFT Fundamental Data Overview February 04, 2026
P/E Forward = 7.5472
P/S = 7.1354
P/B = 5.3878
Revenue TTM = 120.5m EUR
EBIT TTM = -1.85m EUR
EBITDA TTM = 1.39m EUR
Long Term Debt = 1.22m EUR (from longTermDebt, last quarter)
Short Term Debt = 17.6m EUR (from shortTermDebt, last quarter)
Debt = 138.9m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 31.4m EUR (from netDebt column, last quarter)
Enterprise Value = 353.4m EUR (322.0m + Debt 138.9m - CCE 107.5m)
Interest Coverage Ratio = -0.26 (Ebit TTM -1.85m / Interest Expense TTM 7.12m)
EV/FCF = -7.49x (Enterprise Value 353.4m / FCF TTM -47.2m)
FCF Yield = -13.35% (FCF TTM -47.2m / Enterprise Value 353.4m)
FCF Margin = -39.14% (FCF TTM -47.2m / Revenue TTM 120.5m)
Net Margin = -13.68% (Net Income TTM -16.5m / Revenue TTM 120.5m)
Gross Margin = unknown ((Revenue TTM 120.5m - Cost of Revenue TTM 300.0k) / Revenue TTM)
Tobins Q-Ratio = 1.63 (Enterprise Value 353.4m / Total Assets 216.7m)
Interest Expense / Debt = 1.72% (Interest Expense 2.40m / Debt 138.9m)
Taxrate = 18.41% (340.0k / 1.85m)
NOPAT = -1.51m (EBIT -1.85m * (1 - 18.41%)) [loss with tax shield]
Current Ratio = 3.74 (Total Current Assets 155.4m / Total Current Liabilities 41.6m)
Debt / Equity = 2.65 (Debt 138.9m / totalStockholderEquity, last quarter 52.5m)
Debt / EBITDA = 22.54 (Net Debt 31.4m / EBITDA 1.39m)
Debt / FCF = -0.67 (negative FCF - burning cash) (Net Debt 31.4m / FCF TTM -47.2m)
Total Stockholder Equity = 71.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.44% (Net Income -16.5m / Total Assets 216.7m)
RoE = -22.98% (Net Income TTM -16.5m / Total Stockholder Equity 71.8m)
RoCE = -2.54% (EBIT -1.85m / Capital Employed (Equity 71.8m + L.T.Debt 1.22m))
RoIC = -1.28% (negative operating profit) (NOPAT -1.51m / Invested Capital 118.3m)
WACC = 4.76% (E(322.0m)/V(460.9m) * Re(6.21%) + D(138.9m)/V(460.9m) * Rd(1.72%) * (1-Tc(0.18)))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.08%
Fair Price DCF = unknown (Cash Flow -47.2m)
EPS Correlation: 1.85 | EPS CAGR: 210.3% | SUE: 0.0 | # QB: 0
Revenue Correlation: 57.66 | Revenue CAGR: 330.1% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-0.72 | Chg30d=-0.031 | Revisions Net=-1 | Growth EPS=+3.5% | Growth Revenue=-8.5%